Akari Total Stockholder Equity vs Property Plant Equipment Analysis
| AKTX Stock | USD 1.36 0.11 7.48% |
Akari Therapeutics financial indicator trend analysis is way more than just evaluating Akari Therapeutics PLC prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Akari Therapeutics PLC is a good investment. Please check the relationship between Akari Therapeutics Total Stockholder Equity and its Property Plant Equipment accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akari Therapeutics PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
Total Stockholder Equity vs Property Plant Equipment
Total Stockholder Equity vs Property Plant Equipment Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Akari Therapeutics PLC Total Stockholder Equity account and Property Plant Equipment. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Akari Therapeutics' Total Stockholder Equity and Property Plant Equipment is 0.83. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Property Plant Equipment in the same time period over historical financial statements of Akari Therapeutics PLC, assuming nothing else is changed. The correlation between historical values of Akari Therapeutics' Total Stockholder Equity and Property Plant Equipment is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Akari Therapeutics PLC are associated (or correlated) with its Property Plant Equipment. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant Equipment has no effect on the direction of Total Stockholder Equity i.e., Akari Therapeutics' Total Stockholder Equity and Property Plant Equipment go up and down completely randomly.
Correlation Coefficient | 0.83 |
| Relationship Direction | Positive |
| Relationship Strength | Strong |
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Property Plant Equipment
Most indicators from Akari Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Akari Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akari Therapeutics PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. Selling General Administrative is likely to drop to about 10.8 K in 2024. Tax Provision is likely to drop to about (3 M) in 2024
| 2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 10.6K | 45.9K | 41.3K | 70.5K | Interest Income | 10.6K | 45.9K | 41.3K | 39.3K |
Akari Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Akari Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Akari Therapeutics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Common Stock Shares Outstanding | 915.5K | 1.6M | 2.1M | 3.1M | 4.9M | 4.7M | |
| Total Assets | 10.3M | 17.6M | 11.6M | 13.8M | 4.4M | 4.1M | |
| Other Current Liab | 4.2M | 1.8M | 4.3M | 11.1M | 4.6M | 5.9M | |
| Total Current Liabilities | 5.5M | 5.2M | 6.1M | 12.0M | 4.6M | 7.9M | |
| Total Stockholder Equity | 3.8M | 12.4M | 5.6M | 1.8M | (229K) | (217.6K) | |
| Net Debt | (5.7M) | (14.1M) | (9.4M) | (13.2M) | (3.8M) | (4.0M) | |
| Retained Earnings | (138.2M) | (156.6M) | (199.7M) | (217.5M) | (227.5M) | (216.1M) | |
| Accounts Payable | 1.2M | 3.4M | 1.8M | 946.7K | 1.7K | 1.6K | |
| Cash | 5.7M | 14.1M | 9.4M | 13.2M | 3.8M | 3.7M | |
| Cash And Short Term Investments | 5.7M | 14.1M | 9.4M | 13.2M | 3.8M | 3.7M | |
| Common Stock Total Equity | 22.9M | 23.7M | 32.0M | 384.7K | 442.4K | 420.3K | |
| Liabilities And Stockholders Equity | 10.3M | 17.6M | 11.6M | 13.8M | 4.4M | 4.1M | |
| Non Current Liabilities Total | 1.0M | 3.4M | 4.3M | 946.7K | 1.1M | 1.1M | |
| Other Stockholder Equity | 122.3M | 179.6M | 205.3M | 219.3M | 174.8M | 116.1M | |
| Total Liab | 6.5M | 5.2M | 6.1M | 12.0M | 4.6M | 8.1M | |
| Total Current Assets | 10.3M | 17.6M | 11.6M | 13.8M | 4.3M | 4.1M | |
| Accumulated Other Comprehensive Income | (12.2M) | (10.9M) | (541.0K) | (770.8K) | 51.2M | 53.7M | |
| Common Stock | 32.0M | 385K | 476.0K | 744.5K | 1.3M | 1.3M | |
| Non Current Assets Total | 35K | 27K | 22.9K | 16.9K | 14K | 13.3K | |
| Property Plant And Equipment Gross | 20.4K | 5.0K | 172K | 164.9K | 197.8K | 207.7K | |
| Intangible Assets | 30K | 27K | 22.9K | 16.9K | 14.0 | 13.3 | |
| Net Tangible Assets | 3.1M | (1.8M) | 9.4M | 5.5M | 5.0M | 4.7M | |
| Non Currrent Assets Other | 142.2K | 585K | 0.0 | 14.0K | 16.1K | 15.3K | |
| Other Current Assets | 1.0M | 521.9K | 90.3K | 99.5K | 496K | 483.0K | |
| Net Invested Capital | (1.8M) | 9.4M | 5.6M | 1.8M | 1.6M | 1.5M | |
| Net Working Capital | (1.8M) | 9.4M | 5.5M | 1.8M | 1.6M | 1.5M | |
| Capital Stock | 32.0M | 384.7K | 476.0K | 744.5K | 670.0K | 636.5K |
Pair Trading with Akari Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Akari Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akari Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Akari Stock
| 0.76 | EGRX | Eagle Pharmaceuticals Earnings Call This Week | PairCorr |
| 0.79 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
Moving against Akari Stock
| 0.83 | QLI | Qilian International | PairCorr |
| 0.76 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
| 0.75 | IMCC | Im Cannabis Corp Earnings Call This Week | PairCorr |
| 0.53 | PAHC | Phibro Animal Health Earnings Call This Week | PairCorr |
| 0.48 | UPC | Universe Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Akari Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Akari Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Akari Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Akari Therapeutics PLC to buy it.
The correlation of Akari Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Akari Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Akari Therapeutics PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Akari Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akari Therapeutics PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Akari Stock analysis
When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is Akari Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akari Therapeutics. If investors know Akari will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akari Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.04) | Return On Assets (1.16) | Return On Equity (12.81) |
The market value of Akari Therapeutics PLC is measured differently than its book value, which is the value of Akari that is recorded on the company's balance sheet. Investors also form their own opinion of Akari Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akari Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akari Therapeutics' market value can be influenced by many factors that don't directly affect Akari Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akari Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akari Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akari Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.